학술논문

Preliminary Results from a Phase I Study of HMPL-523, a Selective Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Document Type
Journal
Source
BLOOD; NOV 23 2021, 138 4p. Supplement: 1
Subject
Language
English
ISSN
15280020